BBOT
BridgeBio Oncology Therapeutics, Inc.
$8.32
-0.77 (-8.47%)
At close · Jul 10
Market Cap
$666.49M
Shares
80,107,104
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.32
Open$9.11
Day$8.30–9.24
52W$7.00–14.87
Avg vol 30d439K
Short int5.2M · 6.5% float · 7.2d
Short vol88%
DataFeb 2024–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
+2%
above
RSI (14)
53
neutral
MACD trend
Positive
52-week position
17%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+17%
trailing
6-month return
−28%
trailing
YTD return
−34%
this year
Relative strength
−37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
+26% holders QoQ · +23 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.51% of float · ▲ +32.3% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
67 holders — 13F breadth
Squeeze score
78
high risk · 0–100
Fundamentals
EPS growth
+100%
Y/Y
Free cash flow
$-114.5M
Balance sheet
$373.7M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
+2%
Bullish
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $8 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
+26% holders QoQ · +23 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.51% of float · ▲ +32.3% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
67 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $7
Now $8 · 17%
52-wk high $15
vs 200-day avg -20%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BBOT
this stock
BridgeBio Oncology Therapeutics, Inc.
|
$666.49M | -33.5% | — | — | 6.5% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BBOT | +2.6% | +16.9% | -27.7% | +9.2% | -33.6% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +1.2% | +12.8% | -36.7% | +8.1% | -44.3% |